217 related articles for article (PubMed ID: 27572411)
1. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
Barras MA; Serisier D; Hennig S; Jess K; Norris RL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
[TBL] [Abstract][Full Text] [Related]
2. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care.
Brockmeyer JM; Wise RT; Burgener EB; Milla C; Frymoyer A
Pediatr Pulmonol; 2020 Dec; 55(12):3343-3350. PubMed ID: 32827334
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
Gao Y; Hennig S; Barras M
Clin Pharmacokinet; 2019 Mar; 58(3):389-399. PubMed ID: 30140975
[TBL] [Abstract][Full Text] [Related]
4. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
Hennig S; Holthouse F; Staatz CE
Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
[TBL] [Abstract][Full Text] [Related]
5. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
Wang X; Koehne-Voss S; Anumolu SS; Yu J
J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
[TBL] [Abstract][Full Text] [Related]
7. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
Drennan PG; Thoma Y; Barry L; Matthey J; Sivam S; van Hal SJ
Ther Drug Monit; 2021 Aug; 43(4):505-511. PubMed ID: 33941739
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
Burgard M; Sandaradura I; van Hal SJ; Stacey S; Hennig S
Clin Pharmacokinet; 2018 Aug; 57(8):1017-1027. PubMed ID: 29134570
[TBL] [Abstract][Full Text] [Related]
11. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Madsen V; Lind A; Rasmussen M; Coulthard K
J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
[TBL] [Abstract][Full Text] [Related]
13. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
14. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
[TBL] [Abstract][Full Text] [Related]
16. Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods.
Imani S; Fitzgerald DA; Robinson PD; Selvadurai H; Sandaradura I; Lai T
J Antimicrob Chemother; 2022 Nov; 77(12):3358-3366. PubMed ID: 36172897
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
[TBL] [Abstract][Full Text] [Related]
18. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
19. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
20. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update.
Gao Y; Barras M; Hennig S
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263058
[No Abstract] [Full Text] [Related]
[Next] [New Search]